Ibio inc
Business Description
Ibio Inc. is a biotechnology company that focuses on developing and commercializing plant-based pharmaceuticals and vaccines. The company was founded in 2008 and is headquartered in Bryan, Texas.
The core technology of Ibio is its proprietary plant-based expression system, known as the iBioLaunch platform. This platform allows for the rapid and cost-effective production of high-quality proteins, antibodies, and other biologics in plants. By using plants as bioreactors, Ibio is able to bypass many of the limitations and challenges associated with traditional manufacturing methods.
One of the key advantages of the iBioLaunch platform is its scalability. Ibio can quickly scale up production to meet demand, making it an attractive solution for the production of vaccines and other critical medical supplies, especially during times of crisis such as pandemics. This flexibility has positioned Ibio as a leading player in the biotherapeutics market.
In addition to its core platform, Ibio also offers a range of services to support the development and manufacturing of biologics. These services include cell line development, upstream and downstream process development, and analytical testing services. These services enable Ibio to provide end-to-end solutions for its clients, from early-stage development through to commercial manufacturing.
Ibio has a diverse portfolio of collaborations and partnerships with pharmaceutical companies, government agencies, and research institutions. These partnerships provide the company with access to expertise, resources, and funding to advance its research and development efforts. Notable collaborations include agreements with the Infectious Disease Research Institute, the National Institute for Innovation in Manufacturing Biopharmaceuticals, and the Brazilian Ministry of Health.
In recent years, Ibio has made significant progress in advancing its pipeline of product candidates. The company has several programs in various stages of development, targeting a range of indications including fibrotic diseases, oncology, and infectious diseases. Notable candidates include IBIO-201, a therapeutic candidate for the treatment of idiopathic pulmonary fibrosis; IBIO-200, a subunit vaccine for COVID-19; and IBIO-400, a next-generation anthrax vaccine.
Ibio has also made strategic acquisitions to further enhance its capabilities and expand its product portfolio. In 2019, the company acquired the technology assets and certain proprietary rights from AzarGen Biotechnologies, a South African company specializing in the development of biopharmaceuticals. This acquisition has strengthened Ibio*s position in the global biopharmaceutical market and opened new opportunities for growth.
Overall, Ibio Inc. is a forward-thinking biotechnology company that is leveraging its plant-based expression platform to revolutionize the production of biologics. With a strong pipeline, strategic collaborations, and a track record of successful partnerships, Ibio is well-positioned to make a significant impact in the biopharmaceutical industry.
|